TABLE 3.
Differences between outcomes in the two periods of treatment.
| Improvement (≤0) | Mild worsening (1–4 days) | Moderate worsening (5–10 days) | Severe worsening (>10 days) | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MHD | MMD | MHD | MMD | MHD | MMD | MHD | MMD | MHD | MMD | |
| N total | 93 (25.8%) | 101 (29.1%) | 166 (46%) | 198 (57%) | 80 (22%) | 38 (10.9%) | 21 (5.8%) | 10 (2.9%) | >0.9 | >0.9 |
| Sex: female, n (%) | 68 (76%) | 76 (78%) | 138 (83%) | 164 (83%) | 67 (84%) | 30 (79%) | 20 (95%) | 10 (100%) | 0.2 | 0.3 |
| Age at migraine onset, years (IQR) | 20 (14.6) | 20.1 (14.9) | 17.9 (9.5) | 17.6 (8.7) | 16.3 (13.6) | 15.5 (14.6) | 18.9 (18.5) | 13.2 (8.5) | 0.04 | 0.01 |
| Age at anti‐CGRP MAb start, years (IQR) | 48.7 (11.8) | 48.7 (12.7) | 48.8 (12.9) | 48.5 (12.6) | 48.3 (15.4) | 47 (14.8) | 52 (15.7) | 55.2 (11.6) | >0.09 | 0.5 |
| Migraine type: CM | 72 (77%) | 83 (82%) | 107 (64%) | 134 (68%) | 64 (80%) | 30 (79%) | 19 (90%) | 9 (90%) | 0.007 | 0.026 |
| NSAID overuse | 40 (43%) | 42 (42%) | 49 (30%) | 60 (30%) | 30 (38%) | 12 (32%) | 5 (24%) | 5 (50%) | 0.1 | 0.2 |
| Opioids overuse | 2 (2.2%) | 3 (3.0%) | 1 (0.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4.8%) | 1 (10%) | 0.2 | 0.012 |
| Triptans overuse | 42 (45%) | 46 (46%) | 66 (40%) | 83 (42%) | 32 (40%) | 11 (29%) | 6 (29%) | 5 (50%) | 0.5 | 0.3 |
| Time between discontinuation and reintroduction | 4.5 (3) | 4.5 (2.8) | 4.4 (3.7) | 4.2 (3.7) | 4.8 (3.6) | 4.8 (3.7) | 4.3 (2.1) | 4.4 (6.5) | 0.14 | 0.8 |